What We’re Seeing
What You Need to Know About Molecular Point-of-Care and Coronavirus
Given the demand for rapid solutions to identify COVID-19, the time required for new immunoassays and the failure of centralized models so far, Molecular Point-of-Care (mPOC) tests for this new viral threat seem logical. This White Paper from Kalorama Information details where we are now with mPOC systems for this new threat.
Information provided includes:
- The Molecular Point-of-Care Advantage
- Tests Under Development
- CDC Response to COVID-19
- Possible Regulatory Outcomes
- About Kalorama’s Molecular POC Market Study
FEATURED REPORT
Clinical Laboratory Services Market, 5th Edition
This report examines the world and regional markets and is essential for laboratory and IVD companies seeking to better understand the market potential. Included in the report are statistics influencing the industry, incidence of diseases in the U.S. and worldwide demographics, life expectancy, and company strategies
COVID-19 Diagnostics Latest: Abbott IDNOW, Secondary-Use Immunoassays
UncategorizedThere has never been so much focus on IVDs for an infectious disease as we’ve seen in 2020 with COVID-19 diagnostics. Attention has been focused on how to effectively scale up the diagnostic testing, and questions have been asked as to why testing took so long to appear. Kalorama Information is has covered IVD markets […]
Science and Medicine Group Support to Industry’s Fight Against Covid-19
Diagnostics, Healthcare, Infectious DiseaseScience and Medicine Group Inc. including Kalorama Information, SDi, BioInformatics, and IMV are marshaling our information and data resources to help those on the frontline in the fight against the COVID-19 virus. Science and Medicine Group Inc. is a market research and media company serving the life science, analytical instrument, diagnostic, medical imaging and dental […]